The Biotechnician-What are you planning on acquiring from the Curative deal in China, and what is the future of the purchase?
Douglas-Curative Medical is a leading provider of non-invasive ventilation (NIV) and sleep-disordered breathing (SDB) medical devices in China, with strong local R&D manufacturing, sales and marketing capabilities. We have signed a definitive agreement to invest in this innovation-led, high growth company so that we can accelerate the development of China’s sleep and respiratory care markets. Curative will retain their name and branding, and Jason Sun will continue as Curative’s leader. Initially, ResMed and Curative will be strategically aligned but operationally independent. Curative and ResMed customers will continue to receive the same high quality customer service and both the companies’ product lines will be fully supported.
Douglas-Curative’s strong clinical, innovation and market reputation, combined with ResMed’s global leadership in sleep and respiratory medicine will create a strategic partnership to help millions in China and other markets. By partnering with Curative, ResMed is investing to accelerate growth while improving patient quality-of-life and reducing total healthcare system costs.
China is in the top three global medical device markets in the world, with significant unmet needs for SDB and COPD therapies. Together with Curative, we will have the broadest portfolio of innovative NIV and SDB devices, from premium import offers to offers tailored for the needs of the China market. We will bring the advantages of ResMed’s global scale and deep expertise to accelerate Curative’s growth in China and other growth markets over time.
The Biotechnician-What are some of the challenges you are facing in China, and how are you overcoming them?
Douglas-Like many of our markets, there is a significant opportunity to increase awareness about the prevalence and consequences of SDB (sleep disordered breathing). Additionally, there is little reimbursement for medical devices used in the home and patients often pay for their own therapy products. ResMed and Curative will continue to invest in creating awareness of SDB as well as the clinical and economic evidence to support long term treatment of SDB and other chronic respiratory conditions.
The Biotechnician-Your team plans on meeting a global goal of improving 20 million lives by 2020. Would you say that most of those lives would be in China or all over the world?
Douglas-SDB is currently undertreated in every country in the world and we are working globally to address this. The magnitude of impact that ResMed and Curative can have in China in making a positive difference in the lives of tens of millions of people who suffer from sleep apnea, chronic obstructive pulmonary disease (COPD) and other respiratory illnesses is clear. We will continue to raise awareness of SDB and its treatment, in China and around the world. Our acquisition of Curative will certainly help us reach our 20 million lives by 2020 global goal.